- Home
- NBIX
as 07-26-2024 4:00pm EST
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Upcoming Earnings Alert:
Get ready for potential market movements as Neurocrine Biosciences Inc. NBIX prepares to release earnings report on 01 Aug 2024.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 13.5B | IPO Year: | 1996 |
| Target Price: | $156.45 | AVG Volume (30 days): | 675.5K |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.65 | EPS Growth: | 498.36 |
| 52 Week Low/High: | $99.98 - $150.39 | Next Earning Date: | 08-01-2024 |
| Revenue: | $1,982,000,000 | Revenue Growth: | 23.99% |
| Revenue Growth (this year): | 20.03% | Revenue Growth (next year): | 15.23% |
Stock Insider Trading Activity of Neurocrine Biosciences Inc. (NBIX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ABERNETHY MATT | NBIX | Chief Financial Officer | Jul 16 '24 | Sell | $150.04 | 900 | $135,036.99 | 31,528 | SEC Form 4 |
| Delaet Ingrid | NBIX | Chief Regulatory Officer | Jul 16 '24 | Sell | $150.04 | 900 | $135,036.00 | 6,607 | SEC Form 4 |
| Delaet Ingrid | NBIX | Chief Regulatory Officer | Jul 16 '24 | Sell | $150.00 | 1,557 | $233,550.00 | 7,507 | SEC Form 4 |
| Delaet Ingrid | NBIX | Chief Regulatory Officer | Jul 16 '24 | Sell | $150.10 | 400 | $60,041.00 | 7,507 | SEC Form 4 |
| Cooke Julie | NBIX | Chief Human Resources Officer | Jul 16 '24 | Sell | $150.04 | 900 | $135,036.00 | 18,202 | SEC Form 4 |
| Delaet Ingrid | NBIX | Chief Regulatory Officer | Jul 1 '24 | Sell | $138.11 | 272 | $37,565.92 | 7,507 | SEC Form 4 |
| Cooke Julie | NBIX | Chief Human Resources Officer | Jul 1 '24 | Sell | $140.19 | 10,000 | $1,401,864.00 | 18,202 | SEC Form 4 |
| Delaet Ingrid | NBIX | Chief Regulatory Officer | May 31 '24 | Sell | $136.55 | 273 | $37,278.15 | 7,507 | SEC Form 4 |
| SHERWIN STEPHEN A | NBIX | Director | May 29 '24 | Sell | $133.47 | 15,000 | $2,002,009.50 | 26,504 | SEC Form 4 |
| SHERWIN STEPHEN A | NBIX | Director | May 29 '24 | Sell | $133.46 | 25,000 | $3,336,555.00 | 26,504 | SEC Form 4 |
| POPS RICHARD F | NBIX | Director | May 17 '24 | Sell | $141.84 | 2,100 | $297,860.43 | 31,611 | SEC Form 4 |
| Norwalk Leslie V | NBIX | Director | May 17 '24 | Sell | $141.82 | 1,106 | $156,849.93 | 994 | SEC Form 4 |
| Sharp Shalini | NBIX | Director | May 17 '24 | Sell | $141.90 | 1,106 | $156,943.39 | 994 | SEC Form 4 |
| ABERNETHY MATT | NBIX | Chief Financial Officer | May 14 '24 | Sell | $140.24 | 15,000 | $2,103,609.00 | 31,528 | SEC Form 4 |
| ABERNETHY MATT | NBIX | Chief Financial Officer | May 14 '24 | Sell | $135.66 | 15,000 | $2,034,826.50 | 31,528 | SEC Form 4 |
| LYONS GARY A | NBIX | Director | May 14 '24 | Sell | $135.63 | 12,500 | $1,695,370.00 | 116,947 | SEC Form 4 |
| Delaet Ingrid | NBIX | Chief Regulatory Officer | May 6 '24 | Sell | $140.55 | 273 | $38,370.15 | 7,507 | SEC Form 4 |
| BENEVICH ERIC | NBIX | Chief Commercial Officer | Apr 15 '24 | Sell | $133.36 | 7,231 | $964,359.42 | 40,778 | SEC Form 4 |
| BENEVICH ERIC | NBIX | Chief Commercial Officer | Apr 15 '24 | Sell | $133.36 | 12,587 | $1,678,660.22 | 40,778 | SEC Form 4 |
| Delaet Ingrid | NBIX | Chief Regulatory Officer | Apr 1 '24 | Sell | $137.30 | 272 | $37,345.60 | 7,507 | SEC Form 4 |
| Delaet Ingrid | NBIX | Chief Regulatory Officer | Mar 21 '24 | Sell | $145.06 | 5,000 | $725,320.00 | 7,507 | SEC Form 4 |
| BENEVICH ERIC | NBIX | Chief Commercial Officer | Mar 14 '24 | Sell | $139.38 | 5,479 | $763,656.99 | 40,778 | SEC Form 4 |
| BENEVICH ERIC | NBIX | Chief Commercial Officer | Mar 14 '24 | Sell | $139.38 | 69,521 | $9,689,760.51 | 40,778 | SEC Form 4 |
| MORROW GEORGE J | NBIX | Director | Mar 14 '24 | Sell | $139.42 | 20,000 | $2,788,432.00 | 0 | SEC Form 4 |
| MORROW GEORGE J | NBIX | Director | Mar 14 '24 | Sell | $139.41 | 20,000 | $2,788,278.00 | 0 | SEC Form 4 |
Latest Neurocrine Biosciences Inc. News
NBIX Breaking Stock News: Dive into NBIX Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Argus Research
3 days ago
NBIX: Lowering target price to $153.00
MT Newswires
8 days ago
Neurocrine Biosciences Rolls Out Ingrezza Sprinkle Capsules to Treat Tardive Dyskinesia, Chorea With Huntington's Disease
PR Newswire
8 days ago
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
Argus Research
10 days ago
NBIX: Raising target price to $155.00
Zacks
14 days ago
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
PR Newswire
15 days ago
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
Zacks
16 days ago
Top Medical Stocks to Buy for Growth & Performance
Compare NBIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NBIX Neurocrine Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.